Introduction
Immunoglobulin A (IgA) is the predominant immunoglobulin in human secretions and the second most important immunoglobulin in the circulation on a quantitative basis. 1 '2 Depositions of IgA in the glomerular mesangial area of the kidney, as found in IgA nephropathy, are thought to play a crucial role in the inflammatory processes in this disease. The deposited IgA is mainly of the IgA1 subclass and is thought to be derived from the circulation. 4 Also co-depositions of IgG and complement factors, such as complement component 3 (C3) are routinely seen in renal biopsies of patients with IgA nephropathy. 5 Elevated serum levels of IgA, 6 increased production of IgA1, 7 and a hyperresponse for IgA1 after vaccination 7 is found in patients with IgA nephropathy. The mechanisms of IgA deposition in the kidney are still unclear. However, a delayed clearance of IgA has been suggested. Recently, a specific receptor for IgA was described in rat and human renal glomerular mesangial cells (CD89). 9 It is not known whether CD89 plays a role in IgA deposition in 12 It was shown that IL-6 is produced by a variety of cells, such as macrophages, lymphocytes, fibroblasts and endothelial cells. [13] [14] [15] [16] [17] Also, it has been shown that MC are able to produce IL-6,18-2 which acts as an autocrine growth factor for rat mesangial cells in vitro. 2'2 In this study we (Fig. 3) .
To investigate whether the IL-6 produced by the MC upon IgA stimulation is due to de novo synthesis, MC were incubated in triplicate for 72 h in medium, or in medium supplemented with 10 I.tg/ml human dimeric IgA, both with or without cycloheximide (1 btg/ml), and assessed for IL-6. Cycloheximide was able to cause 97.3% inhibition of IgA-induced IL-6 release (p < 0.002) (Fig. 4) . 
